CN110959676A - Fermented milk product containing bifidobacterium lactis and application thereof - Google Patents
Fermented milk product containing bifidobacterium lactis and application thereof Download PDFInfo
- Publication number
- CN110959676A CN110959676A CN201811161152.4A CN201811161152A CN110959676A CN 110959676 A CN110959676 A CN 110959676A CN 201811161152 A CN201811161152 A CN 201811161152A CN 110959676 A CN110959676 A CN 110959676A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium lactis
- cgmcc
- bifidobacterium
- fermented
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 title claims abstract description 118
- 229940009289 bifidobacterium lactis Drugs 0.000 title claims abstract description 118
- 235000014048 cultured milk product Nutrition 0.000 title claims abstract description 17
- 241000894006 Bacteria Species 0.000 claims abstract description 47
- 238000004321 preservation Methods 0.000 claims abstract description 37
- 230000000694 effects Effects 0.000 claims abstract description 29
- 235000021001 fermented dairy product Nutrition 0.000 claims abstract description 26
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 20
- 230000001105 regulatory effect Effects 0.000 claims abstract description 10
- 235000015140 cultured milk Nutrition 0.000 claims description 24
- 239000007858 starting material Substances 0.000 claims description 13
- 235000013361 beverage Nutrition 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 5
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 5
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims description 5
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 3
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 2
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- 241001608472 Bifidobacterium longum Species 0.000 claims description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 2
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 2
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 2
- 229940017800 lactobacillus casei Drugs 0.000 claims description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 235000020122 reconstituted milk Nutrition 0.000 claims description 2
- 235000020185 raw untreated milk Nutrition 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 19
- 241000699670 Mus sp. Species 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 30
- 210000000988 bone and bone Anatomy 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 28
- 238000000855 fermentation Methods 0.000 description 28
- 230000004151 fermentation Effects 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 239000006041 probiotic Substances 0.000 description 22
- 235000018291 probiotics Nutrition 0.000 description 22
- 210000002997 osteoclast Anatomy 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 206010057249 Phagocytosis Diseases 0.000 description 18
- 230000008782 phagocytosis Effects 0.000 description 18
- 230000000529 probiotic effect Effects 0.000 description 16
- 238000003304 gavage Methods 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000008055 phosphate buffer solution Substances 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000011574 phosphorus Substances 0.000 description 9
- 229910052698 phosphorus Inorganic materials 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 102000004067 Osteocalcin Human genes 0.000 description 8
- 108090000573 Osteocalcin Proteins 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 8
- 210000004211 gastric acid Anatomy 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 235000013618 yogurt Nutrition 0.000 description 8
- 241000186000 Bifidobacterium Species 0.000 description 7
- 101800001415 Bri23 peptide Proteins 0.000 description 7
- 101800000655 C-terminal peptide Proteins 0.000 description 7
- 102400000107 C-terminal peptide Human genes 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 102000012422 Collagen Type I Human genes 0.000 description 7
- 108010022452 Collagen Type I Proteins 0.000 description 7
- 102000008108 Osteoprotegerin Human genes 0.000 description 7
- 108010035042 Osteoprotegerin Proteins 0.000 description 7
- 108010025832 RANK Ligand Proteins 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000012981 Hank's balanced salt solution Substances 0.000 description 6
- 102000014128 RANK Ligand Human genes 0.000 description 6
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 6
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 6
- 230000000242 pagocytic effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 206010018910 Haemolysis Diseases 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 210000000628 antibody-producing cell Anatomy 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 241000192125 Firmicutes Species 0.000 description 4
- 241000590002 Helicobacter pylori Species 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 241000192142 Proteobacteria Species 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- -1 calcium supplements Substances 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 229940037467 helicobacter pylori Drugs 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000001539 phagocyte Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 241000605059 Bacteroidetes Species 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 241000588914 Enterobacter Species 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000010855 food raising agent Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 238000009806 oophorectomy Methods 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000605716 Desulfovibrio Species 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010030247 Oestrogen deficiency Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000019541 flavored milk drink Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 235000020200 pasteurised milk Nutrition 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920002449 FKM Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 101000986379 Homo sapiens High mobility group protein HMGI-C Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 description 1
- 101000783348 Naja atra Cytotoxin 1 Proteins 0.000 description 1
- 101000761722 Naja kaouthia Cytotoxin 1 Proteins 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101000983304 Rattus norvegicus Osteocalcin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000006477 desulfuration reaction Methods 0.000 description 1
- 230000023556 desulfurization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000010258 osteoblastogenesis Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Abstract
The invention discloses a fermented milk product containing bifidobacterium lactis and application thereof. Specifically, the invention provides a fermented dairy product, which contains Bifidobacterium lactis (Bifidobacterium lactis) with the preservation number of CGMCC No. 15650. The bifidobacterium lactis with the preservation number of CGMCC No.15650 can exist in the fermented dairy product in an active bacterium or an inactivated form. The fermented dairy product has the effects of preventing osteoporosis, regulating intestinal flora balance and the like.
Description
Technical Field
The invention relates to a fermented milk product containing probiotics and application thereof, in particular to a fermented milk product containing bifidobacterium lactis and application thereof in the aspects of preventing osteoporosis and the like.
Background
Osteoporosis is a systemic metabolic bone disease characterized by a decrease in bone mass and destruction of the bone microstructure. It is manifested by increased bone fragility and susceptibility to fracture. Currently about 2 million people worldwide suffer from osteoporosis. The incidence of hip fractures due to osteoporosis is increasing worldwide, and the elderly population is mostly affected by the risk of fractures. The total number of disabilities per year is 580 million counted worldwide. 51% of this number are due to fractures, occurring primarily in europe and america. Thus, osteoporotic fractures are considered to be a significant cause of mortality and morbidity in developed countries. The most common type of osteoporosis is associated with postmenopausal women aged 50 and older. Of the elderly over age 50, 1/3 women and 1/5 men are threatened by osteoporosis. The survey results of the Ministry of health of China from 2002 to 2005 show that the prevalence rate of osteoporosis is 8.8%, and the prevalence rate of chronic diseases of famous Chinese residents is the third place.
Therapeutic agents for osteoporosis are generally drugs such as injections of hormones, calcium supplements, and bone resorption inhibitors. After long-term administration of drugs or hormones, the drugs or hormones can cause obvious side effects on the organism.
Bifidobacterium lactis (Bifidobacterium lactis) has been reported to have various health effects such as immunomodulation and intestinal health, and has been widely used in fermented milk products such as fermented milk, flavored milk, milk drinks, and the like.
However, there are few technical reports on the use of bifidobacterium lactis for the treatment and/or prevention of osteoporosis.
Disclosure of Invention
The invention provides Bifidobacterium lactis (Bifidobacterium lactis) with an effect of treating and/or preventing osteoporosis, and accordingly provides a fermented dairy product containing the Bifidobacterium lactis or active substances thereof.
In one aspect, the present invention provides a Bifidobacterium lactis (Bifidobacterium lactis) which can be used for treating or preventing osteoporosis and has the effects of increasing calcium ions and/or phosphorus ions in blood. The lack of acid resistance and gastrointestinal fluid resistance is a common property of bifidobacteria, which results in bifidobacteria being difficult to reach and colonize the gut via gastric juices. The Bifidobacterium lactis (Bifidobacterium lactis) provided by the invention has gastric acid resistance and intestinal juice resistance, the survival rate of viable bacteria is more than 62% when the Bifidobacterium lactis is treated in gastric acid solution with pH of 2.5 for 30min, and the survival rate of viable bacteria is more than 61% when the Bifidobacterium lactis is treated for 2 hours; the survival rate of viable bacteria is more than 70 percent after the intestinal juice with pH6.8 is treated for 2 hours.
In the present invention, Bifidobacterium lactis (Bifidobacterium lactis) is provided and named BL-99. The strain has been preserved in China general microbiological culture Collection center (CGMCC) (address: No. 3 Xilu-Beijing province No.1, Beijing Korean district, Ministry of China microbiology institute) 26.04.2018, and is named after classification: bifidobacterium lactis (Bifidobacterium lactis); the preservation number is CGMCC No. 15650.
The study of the invention finds that the bifidobacterium lactis BL-99 (namely the bifidobacterium lactis with the preservation number of CGMCC No. 15650) can be used for treating or preventing osteoporosis, and has the function of improving the concentration of calcium ions and/or phosphorus ions in blood, and the study specifically comprises the following steps: significantly reduce the loss of bone mass caused by estrogen deficiency; the blood calcium and phosphorus concentrations are improved; the amount of osteoclast in vivo and the absorption effect of osteoclast on bone are inhibited by adjusting the proportion of OPG/RANKL; the expression of the protein of the bone anabolism related factor gene, such as alkaline phosphatase and osteocalcin, is promoted, so that the level of the protein is improved, and the formation of new bone is promoted.
The research of the invention also finds that the bifidobacterium lactis BL-99 can be used for enhancing the immune response of an organism, and specifically comprises the following components: the carbon clearance index of the mouse can be improved; improving half hemolysis value of the mouse; increasing the number of mouse antibody-producing cells; activating NK cell activity; delayed immunoreaction is positive; the phagocytic rate and phagocytic index of macrophages are increased.
The study of the invention also finds that the bifidobacterium lactis BL-99 has the capacity of promoting the growth of intestinal bifidobacteria and lactic acid bacteria, can inhibit the growth of vibrio desulfovibrio and/or enterobacter in the intestinal tract, and particularly can inhibit the growth of helicobacter pylori and/or escherichia-shigella. Moreover, researches show that BL-99 dead bacteria have better inhibiting effect on pathogenic bacteria such as helicobacter pylori and Escherichia-Shigella than live bacteria. In addition, mouse experiments show that the strain has no oral acute toxicity and no antibiotic tolerance, and can be safely used for food processing.
Bifidobacterium lactis BL-99 of the present invention can be cultured by anaerobic fermentation in a culture medium for Bifidobacterium lactis (e.g., TPY medium, BBL medium, etc.) which is commonly used in the art. The optimal fermentation temperature is 35-38 ℃, and the optimal fermentation time is 7-24 h. The invention also provides a preparation method of the fermentation culture product of the bifidobacterium lactis BL-99, which comprises the step of carrying out anaerobic culture on the strain in a liquid fermentation culture medium to obtain a fermentation liquid containing the strain. The fermentation liquor can be directly used as a liquid bacterial preparation or further concentrated, and the fermentation liquor can be dried to prepare bacterial powder, or the bacterial powder is prepared by separating thalli from the fermentation liquor. The liquid bacterial preparation of the present invention may be a liquid bacterial preparation prepared by suspending the bacterial cells in a culture medium, a buffer solution, deionized water or other solvent. The BL-99 liquid bacterium preparation or the solid bacterium preparation (bacterium powder) can be stored in a viable bacterium form and has better stability in a storage period. The BL-99 liquid bacteria preparation or solid bacteria preparation (bacteria powder) of the present invention can also be preserved in the form of inactivated dead bacteria. The bacterial preparation can be used for preparing the fermented dairy product.
Further, the present invention provides a fermented milk product comprising Bifidobacterium lactis (Bifidobacterium lactis) having a accession number of CGMCC No. 15650.
According to a particular embodiment of the invention, the fermented milk product of the invention may be a fermented milk, a flavoured fermented milk or a fermented milk beverage, of the live or sterile type.
According to a specific embodiment of the invention, in the fermented milk product of the invention, the bifidobacterium lactis with the preservation number of CGMCC No.15650 exists in the fermented milk product in an active bacterium or an inactivated form.
The live-bacterium fermented milk, flavored fermented milk or fermented milk beverage of the present invention may be prepared by fermentation with a starter strain comprising bifidobacterium lactis having a preservation number of CGMCC No.15650, or may be prepared by adding bifidobacterium lactis having a preservation number of CGMCC No.15650 to a fermented milk base material.
The sterilized fermented milk, flavored fermented milk or fermented milk beverage of the present invention may be prepared by fermenting a starter strain comprising bifidobacterium lactis having a preservation number of CGMCC No.15650 and sterilizing the fermented milk, may be prepared by adding bifidobacterium lactis having a preservation number of CGMCC No.15650 to a fermented milk base material and sterilizing the fermented milk base material, or may be prepared by adding bifidobacterium lactis having a preservation number of CGMCC No.15650 to a sterilized fermented milk base material.
The specific raw material composition and the production method of the fermented milk, the flavored fermented milk, or the fermented milk beverage of the present invention can be performed by referring to the operation of the fermented milk, the flavored fermented milk, or the fermented milk beverage in the prior art.
According to a specific embodiment of the invention, the content of the bifidobacterium lactis with the preservation number of CGMCC No.15650 in the fermented dairy product is 1.0 x103CFU/mL～1.0×1010CFU/mL; alternatively, the Bifidobacterium lactis having a storage number of CGMCC No.15650 is 0.001 to 100mg/mL, preferably 0.01 to 100mg/mL, more preferably 0.01 to 10mg/mL in terms of the weight of the cells, based on 100% by weight of the total weight of the fermented milk product. The content of the bifidobacterium lactis calculated by CFU is preferably the fermented milk product which is suitable for the bifidobacterium lactis with the preservation number of CGMCC No.15650 and exists in the form of active bacteria. The content of the bifidobacterium lactis based on the weight of the strain is preferably the fermented milk product in which the bifidobacterium lactis with the preservation number of CGMCC No.15650 exists in an inactivated form.
According to some embodiments of the invention, the fermented dairy product of the invention is prepared by taking fresh milk or reconstituted milk as a raw material, adding or not adding other raw materials, sterilizing, inoculating a starter strain of bifidobacterium lactis with the preservation number of CGMCC No.15650, and fermenting.
In some more specific embodiments of the invention, the starter strain is bifidobacterium lactis having a accession number of CGMCC No. 15650. Namely, the fermented dairy product is prepared by fermenting a single bacterium of bifidobacterium lactis with the preservation number of CGMCC No. 15650. The process conditions of single-strain fermentation are as follows: the optimal fermentation temperature is 35-38 ℃, and the optimal fermentation time is 7-24 h.
In other more specific embodiments of the invention, the starter strains include bifidobacterium lactis with the preservation number of CGMCC No.15650 and also include mixed strains of streptococcus thermophilus and lactobacillus bulgaricus, and the ratio of the number of the viable streptococcus thermophilus to the number of the viable lactobacillus bulgaricus is 1: 1-1: 2 in general. Namely, the fermented dairy product is prepared by fermenting a composite bacterium containing bifidobacterium lactis with the preservation number of CGMCC No. 15650. Further, the starter strain may further include one or more of lactobacillus acidophilus, other bifidobacterium lactis (bifidobacterium lactis except for bifidobacterium lactis with the preservation number of CGMCC No. 15650), bifidobacterium longum, bifidobacterium breve, bifidobacterium infantis, bifidobacterium adolescentis, bifidobacterium bifidum, lactobacillus helveticus, lactobacillus casei and lactobacillus rhamnosus. According to the preferred embodiment of the invention, the using amount of the bifidobacterium lactis with the preservation number of CGMCC No.15650 (calculated by the mass of the bifidobacterium lactis) is not more than 0.5 per mill of the total weight of the fermented dairy product during the fermentation of the complex bacteria. The dosage and compounding proportion of other strains and the fermentation process conditions can be carried out according to the conventional operation in the field. When the compound bacteria containing streptococcus thermophilus are fermented, the preferable fermentation process conditions are as follows: the fermentation temperature is 40-43 ℃, and the fermentation time is 3-12 h.
The fermented dairy product provided by the invention has the corresponding effects of preventing and treating osteoporosis, regulating the balance of gastrointestinal flora, improving immunity and the like due to the inclusion of the bifidobacterium lactis BL-99.
Therefore, on the other hand, the invention also provides the application of the bifidobacterium lactis with the preservation number of CGMCC No.15650 in preparing the fermented dairy product with the effect of preventing osteoporosis.
On the other hand, the invention also provides application of the bifidobacterium lactis with the preservation number of CGMCC No.15650 in preparing the fermented dairy product with the effect of regulating the balance of gastrointestinal flora.
On the other hand, the invention also provides the application of the bifidobacterium lactis with the preservation number of CGMCC No.15650 in preparing the fermented dairy product with the effect of improving the immunity.
In conclusion, the invention provides a fermented dairy product containing bifidobacterium lactis with the preservation number of CGMCC No.15650, which has the effects of preventing and treating osteoporosis, regulating the balance of gastrointestinal flora, improving immunity and the like.
Drawings
Figure 1A shows the change in body weight of animals before and after intervention with bifidobacterium lactis BL-99. Figure 1B shows the change in uterine weight of animals before and after intervention with bifidobacterium lactis BL-99.
Fig. 2A shows the outcome of post-HE staining for bifidobacterium lactis BL-99. Fig. 2B shows the change in percentage of trabecular area before and after intervention with bifidobacterium lactis BL-99.
Fig. 3A shows results of tibial TRAP staining following bifidobacterium lactis BL-99 intervention. FIG. 3B shows the change in the percentage of osteoclasts on the bone surface (OcS/BS) before and after intervention by Bifidobacterium lactis BL-99.
FIGS. 4A to 4D show the changes in serum calcium, serum phosphorus, serum osteocalcin, type I collagen C-terminal peptide after the Bifidobacterium lactis BL-99 is dried, respectively.
Fig. 5A-5E show the effect of bifidobacterium lactis BL-99 intervention on the regulation of genes associated with bone metabolism.
FIG. 6 is a schematic view of a fermentation process according to an embodiment of the present invention.
Microbial preservation of the patent procedure:
bifidobacterium lactis BL-99 of the present invention:
the preservation date is as follows: 26/04/2018;
the preservation unit: china general microbiological culture Collection center (CGMCC);
the address of the depository: xilu No.1 Hospital No. 3, the institute of microbiology, China academy of sciences, Beijing, Chaoyang
The preservation number is: CGMCC No. 15650;
and (3) classification and naming: bifidobacterium lactis (Bifidobacterium lactis).
Detailed Description
For a more clear understanding of the technical features, objects and advantages of the present invention, reference is now made to the following detailed description taken in conjunction with the accompanying specific embodiments, and the technical solutions of the present invention are described, it being understood that these examples are intended to illustrate the present invention and are not intended to limit the scope of the present invention. In the examples, each raw reagent material is commercially available, and the experimental method not specifying the specific conditions is a conventional method and a conventional condition well known in the art, or a condition recommended by an instrument manufacturer.
Unless specifically defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the relevant art. Unless otherwise indicated, all numbers expressing quantities of ingredients, cell culture, processing conditions, and so forth used in the present disclosure are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters are approximations and may vary depending upon the desired properties sought to be obtained by the present invention. The term "at least" preceding a series of elements is to be understood as referring to each element in the series, unless otherwise indicated.
In various examples of the invention, experimental data are expressed as Mean ± s.e.m. data were counted using PRISM version5.0(GraphPad, San Diego, CA, USA). Differences between groups were counted using one-way ANOVA followed by Tukery's smart composition test. There were significant statistical differences at P < 0.05.
Example 1: bifidobacterium lactis BL-99 and performance measurement thereof
The bifidobacterium lactis BL-99 of the invention is obtained from Shanghai Bingzhui GmbH and is separated from the intestinal tract of the infant. The strain has been preserved in China general microbiological culture Collection center (CGMCC) (address: No. 3 Xilu-Beijing province No.1, Beijing Korean district, Ministry of China microbiology institute) 26.04.2018, and is named after classification: bifidobacterium lactis (Bifidobacterium lactis); the preservation number is CGMCC No. 15650.
1. Taxonomical characterization of Bifidobacterium lactis BL-99
The results of the physical and chemical tests are as follows:
16S rRNA Gene sequence sequencing results (SEQ ID No. 1):
GCTCCCCCACAAGGGTCGGGCCACCGGCTTCGGGTGCTACCCACTTTCATGACTTGACGGGCGGTGTGTACAAGGCCCGGGAACGCATTCACCGCGGCGTTGCTGATCCGCGATTACTAGCGACTCCGCCTTCACGCAGTCGAGTTGCAGACTGCGATCCGAACTGAGACCGGTTTTCAGCGATCCGCCCCACGTCACCGTGTCGCACCGCGTTGTACCGGCCATTGTAGCATGCGTGAAGCCCTGGACGTAAGGGGCATGATGATCTGACGTCATCCCCACCTTCCTCCGAGTTGACCCCGGCGGTCCCACATGAGTTCCCGGCATCACCCGCTGGCAACATGCGGCGAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACGACCATGCACCACCTGTGAACCGGCCCCGAAGGGAAACCGTGTCTCCACGGCGATCCGGCACATGTCAAGCCCAGGTAAGGTTCTTCGCGTTGCATCGAATTAATCCGCATGCTCCGCCGCTTGTGCGGGCCCCCGTCAATTTCTTTGAGTTTTAGCCTTGCGGCCGTACTCCCCAGGCGGGATGCTTAACGCGTTGGCTCCGACACGGGACCCGTGGAAAGGGCCCCACATCCAGCATCCACCGTTTACGGCGTGGACTACCAGGGTATCTAATCCTGTTCGCTCCCCACGCTTTCGCTCCTCAGCGTCAGTGACGGCCCAGAGACCTGCCTTCGCCATTGGTGTTCTTCCCGATATCTACACATTCCACCGTTACACCGGGAATTCCAGTCTCCCCTACCGCACTCCAGCCCGCCCGTACCCGGCGCAGATCCACCGTTAGGCGATGGACTTTCACACCGGACGCGACGAACCGCCTACGAGCCCTTTACGCCCAATAAATCCGGATAACGCTCGCACCCTACGTATTACCGCGGCTGCTGGCACGTAGTTAGCCGGTGCTTATTCGAACAATCCACTCAACACGGCCGAAACCGTGCCTTGCCCTTGAACAAAAGCGGTTTACAACCCGAAGGCCTCCATCCCGCACGCGGCGTCGCTGCATCAGGCTTGCGCCCATTGTGCAATATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGCCGTATCTCAGTCCCAATGTGGCCGGTCACCCTCTCAGGCCGGCTACCCGTCAACGCCTTGGTGGGCCATCACCCCGCCAACAAGCTGATAGGACGCGACCCCATCCCATGCCGCAAAAGCATTTCCCACCCCACCATGCGATGGAGCGGAGCATCCGGTATTACCACCCGTTTCCAGGAGCTATTCCGGTGCACAGGGCAGGTTGGTCACGCATTACTCACCCGTTCGCCACTCTCACCCCGACAGCAAGCTGCCAGGGATCCCGTTCGACT
2. tolerance of bifidobacterium lactis BL-99 to artificial gastric juice and intestinal juice
Bifidobacteria are genera that are generally not acid-fast. In this example, the tolerance of bifidobacterium lactis BL-99 of the present invention to artificial gastric juice and intestinal juice was tested, and bifidobacterium lactis which had been recognized in the art as having excellent acid resistance and survived through the gastrointestinal tract
For comparison.
The test method comprises the following steps: culturing Bifidobacterium lactis BL-99 strain in MRS liquid culture medium at 37 deg.C for 16 hr, centrifuging at 4 deg.C and 2500rpm for 10min, and collecting thallus.
Respectively culturing the strains to be tested in artificial gastric juice and artificial small intestine juice, processing at 37 ℃ for 0, 30min and 2h, and then performing viable count analysis to evaluate the acid resistance and intestinal juice resistance of the strains according to the survival rate. Survival rate (viable cell count after treatment/viable cell count at time 0) × 100%.
The survival rate detection result of the bacterial strain in artificial gastric acid (pH2.5) is shown in Table 1, the survival rate of the viable bacteria is 7.04% when BB-12 is treated in the artificial gastric acid (pH2.5) for 30min, and the survival rate of the viable bacteria is only 1.64% after 2 hours of treatment; the survival rate of the live bacteria of the bifidobacterium lactis BL-99 is 62.60 percent when the bifidobacterium lactis BL-99 is treated in artificial gastric acid (pH2.5) for 30min, and the survival rate of the live bacteria is 61.83 percent when the bifidobacterium lactis BL-99 is treated for 2 hours. The bifidobacterium lactis BL-99 disclosed by the invention has excellent gastric acid resistance and can smoothly pass through the stomach to reach the intestinal tract to play a probiotic role.
TABLE 1 survival rate of the strains in artificial gastric acid (pH2.5)
The survival rate of the strain in the artificial small intestine solution (pH6.8) is tested and shown in Table 2. The data show that the viable bacteria survival rate of BB-12 in artificial small intestine solution (pH6.8) for 2 hours is only 28.95%; the viable bacteria survival rate of the bifidobacterium lactis BL-99 is 70.23 percent when the bifidobacterium lactis BL-99 is treated in artificial gastric acid (pH2.5) for 2 hours. The bifidobacterium lactis BL-99 disclosed by the invention has excellent intestinal juice resistance and can survive and colonize in intestinal tracts.
TABLE 2 survival rate of the strains in artificial intestinal juice (pH6.8)
3. Toxicity experiment and safety detection of bifidobacterium lactis BL-99
Inoculating the bifidobacterium lactis BL-99 of the invention into a BBL liquid culture medium, carrying out anaerobic culture for 48 +/-2 hours at 36 +/-1 ℃, and counting the viable count of the bifidobacterium lactis BL-99 in the culture solution to be 3.7 multiplied by 108cfu/mL, stock solutions and 5-fold concentrates of the cultures were continuously gavaged to 20.0mL/kg BW for 3 days and observed for 7 days. The experiment was performed with a control group of 5-fold concentrated solution and a stock solution of the medium. The test result shows that: the BBL culture stock solution and 5-fold concentrated solution of Bifidobacterium lactis BL-99 had no statistical effect on the weight gain of mice (p > 0.05) compared with the respective control group, and no toxic reaction or death of the tested mice was observed.
The antibiotic sensitivity of the bifidobacterium lactis BL-99 is evaluated by adopting an SN/T1944-2007 method of determination of bacterial resistance in animals and products thereof. The evaluation results show that the bifidobacterium lactis BL-99 is sensitive to Ampicillin Ampicillin, penicillin G Penicillin G, Erythromycin Erythromycin, Chloramphenicol Chloramphenicol, Clindamycin Clindamycin, Vancomycin Vancomycin, Tetracycline and the like. Meets the requirements of European food Safety Committee (European food Safety Authority) on the evaluation specification of the resistance of the edible bacteria. The bifidobacterium lactis BL-99 does not contain exogenous antibiotic resistance genes and is safe to eat.
4. Detection of efficacy of preventing and treating osteoporosis
4.1 Deovariectomized rat animal models and probiotic intervention
Culturing Bifidobacterium lactis BL-99 strain in MRS liquid culture medium at 37 deg.C for 16 hr, centrifuging at 4 deg.C and 2500rpm for 10min, collecting thallus, washing with Phosphate Buffer Solution (PBS), freeze drying, and storing at-18 deg.C or below. Is used for experimental research of the efficacy detection of preventing and treating osteoporosis.
85 adult female SD rats with the age of 17 weeks with the body weight of 200-300 g. The rats were randomly divided into 3 groups of 10 rats each. 20 rats were subjected to ovariectomy, and the remaining 10 rats were subjected to sham surgery. Rats were exposed to light/dark for 12h daily at room temperature around 25 ℃ with free access to water. After 12 weeks of surgical intervention, animals in the model investigation group are sacrificed, samples of uterus, thighbone, shinbone and the like are collected, and osteoporosis related indexes such as uterus coefficient, bone microstructure morphology, bone structure model parameters and the like are measured.
After the animal after operation has a rest for two weeks, the animal begins to be administered by gavage, and the treatment course is once a day for 12 weeks continuously. Feeding BL-99 probiotics to ovariectomized rats, and feeding distilled water to a sham operation group and an ovariectomized blank control group; the animals were dosed as follows:
the specific grouping of animals is as follows:
group 1-sham blank control (sham), 10, blank solvent;
group 2-ovariectomized blank control group (OVX), 10, blank solvent;
group 3-Deovariectomized + Probiotics BL-99 group, 10, Probiotics dose 109CFU/mL。
The body weight changes of the animals before and after the intervention are shown in fig. 1A. After successful model establishment, the weight of the sham-operated group was significantly lower than that of each of the other ovariectomized groups, consistent with significant weight gain in postmenopausal women. Each intervention group had some increase in body weight during the 12 week intervention period. Compared with the ovariectomized blank group and the ovariectomized probiotic BL-99 intervention group, the weight of the ovariectomized blank group has no significant difference before and after the intervention.
After 12 weeks of dry prognosis, the animals were sacrificed, the weight of the uterus was collected, weighed and recorded, and the uterine coefficient (i.e., the ratio of the weight of the uterus to the weight of the body) was calculated. The experimental results (fig. 1B) show that there is a very significant difference in uterine coefficients between the ovariectomized OVX group and the sham operated group (P <0.001vs. sham operated), indicating significant atrophy of the uterus following ovariectomy with a decrease in vivo estrogen. And the ovariectomized blank group and the ovariectomized + probiotic BL-99 intervention group have no influence on the weight of the uterus, which indicates that the ovariectomized blank group and the ovariectomized + probiotic BL-99 intervention group have no estrogen-like side effect.
4.2 bone histomorphometry
The proximal tibia 1/3 is cut along the sagittal plane and the material is selected at 1X 0.5cm3Soaking in 10% EDTA/PBS (pH7.4) as decalcifying liquid for about 1 week, changing liquid every 3 days, dehydrating, embedding in paraffin, staining by HE along sagittal plane (thickness of 4 μm), determining total tissue area, trabecular area and total girth of trabecular by pathological image analyzer,then the area percentage of the trabecular bone, the number of the trabecular bone, the thickness of the trabecular bone and the separation degree of the trabecular bone are converted by a calculation formula. The bone tissue slices are also used for observing the appearance, arrangement, morphological structure integrity and the like of the trabeculae.
After probiotic BL-99 intervenes for 12 weeks, HE staining results (figure 2A) show that the trabecular bone of the sham operation group is closely arranged and has a complete structure; and compared with the false operation group, the area percentage of the trabecular bone is obviously reduced (P <0.001vs. the false operation). Compared with the OVX blank group, the probiotic BL-99 group can increase the trabecular bone area percentage by about 12.5% (OVX: 16.8 +/-2.5%, OVX + BL-99:18.9 +/-1.8) (P <0.05vs. OVX) (figure 2B), and the probiotic BL-99 can inhibit bone loss caused by estrogen deficiency and has a certain protection effect on bones.
Osteoclasts are the major cells responsible for bone resorption in the body and play an important role in bone development, growth, repair, and remodeling. Osteoclasts are derived from the monocyte-macrophage system and are specialized terminally differentiated cells that can be formed into large multinucleated cells from their mononuclear precursor cells by cell fusion. Osteoclasts correspond functionally to osteoblasts. The two are synergistic and play an important role in the development and formation of bones. Highly expressed tartrate-resistant acid phosphatase (TRAP) is one of the major markers of osteoclasts. Results of tibial TRAP staining are shown in fig. 3A, with positive staining as a result of staining wine red to the osteoclast cytoplasm. The number of osteoclasts stained by TRAP on the surface of tibia in the rats in the OVX blank group was significantly higher than that in the sham-operated rats. Compared with OVX blank rats, the number of TRAP-stained osteoclasts in the probiotic BL-99 group is significantly reduced by about 17.9% (OVX: 22.3 + -1.1%, OVX + BL-99:18.3 + -0.6) (P <0.05vs. In vivo, estrogen can inhibit the activity of osteoclast, and induce the apoptosis of osteoclast so as to play the role of bone resorption resistance. In OVX animals, the inhibitory effect on osteoclasts was lost due to significantly lower estrogen levels, the number of osteoclasts and the ability to resorb bone were significantly increased (fig. 3B), and the final result was a significant decrease in cancellous bone mass. The results from fig. 2A, 2B and 3A, 3B suggest that BL-99 intervention inhibits OVX-induced loss of bone mass, possibly by reducing the number of osteoclasts.
4.3 measurement of Biochemical indicators
The biochemical indicators measured include blood calcium, blood phosphorus, serum Osteocalcin (OCN), type I collagen C-terminal peptide (C-terminal peptides of type I collagen, CTX-I). The method adopts atomic absorption spectrophotometry to measure the blood calcium and the blood phosphorus, and the serum sample is directly measured. The kit for detection comprises: calcum
Test(REF0155-225)，Phosphorus
Test (REF 0830-. However, compared with the OVX blank group, the probiotic BL-99 dry group can obviously improve high serum calcium ions (OVX: 2.28 +/-0.02 mg/dl, OVX + BL-99:2.49 +/-0.03 mg/dl) by about 10 percent and phosphorus ions (OVX: 1.02 +/-0.08 mg/dl, OVX + BL-99:1.41 +/-0.11 mg/dl) by about 40 percent.
Serum osteocalcin is an active polypeptide secreted by osteoblasts and plays an important role in regulating bone metabolism, with levels reflecting osteoblast activity. The C-terminal peptide of type I collagen is a small fragment of type I collagen after degradation, and the content and change of the C-terminal peptide can evaluate the bone resorption state. Serum osteocalcin and type I collagen C-terminal peptide were measured using an ELASA kit, and the measurement was performed according to the instructions in the kit. The kit used for detection is as follows: the Rat Osteocalcin ELISA Kit, Rat C-telopeptide of collagen alpha-1(I) chain ELISA Kit, was SAB (SAbiosciences, USA).
As shown in FIGS. 4A-4D, compared with the OVX blank group, the probiotic BL-99 dried group significantly increased serum osteocalcin levels by about 44.6% (OVX: 68.6 + -16.4 pg/dl, OVX + BL-99:92.6 + -24.3 pg/dl) and decreased serum type I-collagen C-terminal peptide by about 14.6%, but had no statistical significance.
4.4 detection of bone specimen PCR
This example continues to study and examine gene expression in bone specimens associated with osteoclastogenesis and osteoblastogenesis. The intervention mode of the probiotics BL-99 is the same as the previous intervention mode. After total RNA was extracted from bone tissue using Trizol, the RNA was reverse transcribed into cDNA using a reverse transcription kit, followed by PCR amplification using different gene primers (see table below).
Compared with an OVX blank control group, the probiotic BL-99 intervention group can obviously improve the gene expression of Osteoprotegerin (OPG) without obviously influencing the gene expression of RANKL, so that the ratio of OPG/RANKL is increased. RANKL binds to RANK receptors on the surface of osteoclasts, promotes differentiation and activation of osteoclasts, and inhibits apoptosis thereof; osteoprotegerin OPG prevents binding of RANKL to RANK, thereby preventing osteoclast activation, inhibiting osteoclast function, reducing bone resorption, and acting as a negative regulator. The ratio of OPG/RANKL suggests that osteoclast levels are regulated in vivo. The research finds that the expression ratio of OPG/RANKL gene is increased after BL-99 intervention, the ratio is increased by about 75% from 1 to 1.75 of an ovariectomized blank group, and the result indicates that BL-99 has an obvious effect of inhibiting osteoclast formation. In addition, as shown in fig. 5A to 5E: compared with an OVX blank group, the BL-99 intervention group can improve the gene expression level of osteocalcin by about 1.1 times (OVX: 0.908 +/-0.107, OVX + BL-99: 2.075 +/-0.643) and alkaline phosphatase by about 37.8% (OVX: 0.990 +/-0.217, OVX + BL-99: 1.364 +/-0.513), and the expression water of the two genes is closely related to the bone formation capacity, so that BL-99 intervention can promote the formation of new bone and antagonize the loss of bone mass caused by OVX by promoting the expression of related genes of the bone formation.
The results of the above studies confirm that: the bifidobacterium lactis BL-99 can obviously inhibit the loss of bone mass caused by ovariectomy or low estrogen, and improve the blood calcium and the blood phosphorus.
5. Immunomodulatory activity assay
Culturing Bifidobacterium lactis BL-99 strain in MRS liquid culture medium at 37 deg.C for 16 hr, centrifuging at 4 deg.C and 2500rpm for 10min, collecting thallus, washing with Phosphate Buffer Solution (PBS), freeze drying, and storing at-18 deg.C or below. The experimental studies used in this example.
700 healthy male BALB/C mice, 6-8 weeks old, 16-18g, were provided by the laboratory animal technology, Inc., Viton, Beijing. The animal is bred in animal laboratories of the occupational health and poisoning control institute of the Chinese disease prevention and control center: maintaining the room temperature (25 + -2 deg.C), relative humidity (55 + -2)%, and lighting for 12h/12h, and freely eating and drinking.
Animals were randomly divided into 5 groups for each experimental study of this example, 140 mice per group, 1 normal control group per group, and 1 dose group per probiotic sample.
The test sample is administered to the mouse in an intragastric manner for 28 days, the intragastric volume is 0.2mL/10g once a day, and the control group is administered with distilled water by intragastric administration.
According to the probiotic sample information, the dosage of each test sample to be given to the mice is calculated by referring to the daily human body demand and the conversion coefficient of the dosage of 70Kg adults and 20g mice, the dosage of BB-12 group is 2.36mg/Kg, and the dosage of BL-99 group is 6.34 mg/Kg.
5.1 monocyte-macrophage function
5.1.1 carbon Clearance test
Animals were continuously given the sample for 28 days, weighed, injected with India ink in the tail vein, and 20. mu.L of blood was collected at 2min and 10min after the injection, added to 2M of L0.1% sodium carbonate solution, and measured for OD at 600 nm. Mice were sacrificed, livers and spleens were removed, blood stains on the surfaces of the visceral organs were blotted with filter paper and weighed.
The phagocytosis index is used for expressing the carbon clearance capacity of the mouse, and the calculation is carried out according to a formula
The results of the phagocytic index of carbon clearance experiments are shown in table 3. The results show that the phagocytosis index of the mouse carbon clearance test of the BL-99 group is lower than that of the control group, and the mouse carbon clearance test of the BB-12 has no significant difference compared with the control group (p is more than 0.05).
TABLE 3 phagocytic index results in carbon clearance experiments
| Group by group | Animal number (only) | Phagocytic index | P-value compared with |
| Control | |||
| 8 | 7.64±0.62 | -- | |
| BB-12 |
8 | 7.56±0.61 | 0.902 |
| BL-99 group | 9 | 6.43±0.55 | 0.039* |
5.1.2 measurement of organ/body weight ratio
Weighing the initial weight and the final weight of the mouse 28 days after sample administration respectively, dislocating and killing the mouse, taking the spleen and the thymus, removing fascia, sucking blood stains on the surfaces of organs by using filter paper, weighing, and calculating the ratio of the spleen to the body weight and the ratio of the thymus to the body weight.
The results are shown in Table 4. After the test sample is given, compared with the control group, the spleen/body weight ratio and the thymus/body weight ratio of the BL-99 and BB-12 groups have no significant difference, which indicates that the samples BL-99 and BB-12 have no influence on the spleen/thymus of the mice.
TABLE 4 change in organ/body weight ratio of mice
5.2 humoral immune assay
5.2.1 serum hemolysin half maximal hemolysis value (HC)50) Measurement of (2)
Animals were immunized by intraperitoneal injection of 0.2mL SRBC per mouse 28 days after serial dosing. After 4 days, the eyeball is removed, blood is taken out of the 1.5mL centrifugal tube, the centrifugal tube is placed for about 1h at 4 ℃ to ensure that serum is fully separated out, and the centrifugal tube is centrifuged at 2000r/min for 10min to collect the serum. Serum was diluted 100-fold with SA buffer. Adding diluted serum into 96-well plate, adding 100 μ L of the diluted serum into each well, sequentially adding 10% (v/v) SRBC50 μ L and complement 100 μ L (diluted with SA solution at a ratio of 1: 8), placing in 37 deg.C constant temperature water bath, keeping the temperature for 30min, and centrifuging at 1500r/min for 10 min. Then 50 mu L of supernatant is taken from each sample well and blank control well, added into another 96-well culture plate, added with 150 mu L of Wen Chi reagent, provided with half of hemolysis wells simultaneously, added with 12.5 mu L of 10% (v/v) SRBC, added with the Wechi Chi reagent to 200 mu L, fully and uniformly mixed by using a shaking period, placed for 10min, and measured with a full-automatic enzyme standard instrument at 540 to obtain the optical density value of each well.
The amount of hemolysin is expressed as the half hemolysis value (HC50) and is calculated according to the following formula:
the results are shown in Table 5. As can be seen from Table 5, the hemolytic value of HC50 was increased in half (p < 0.05) for both BL-99 and BB-12 groups compared to the control group, and BL-99 group was higher than BB-12 group.
TABLE 5 values of the median hemolysis HC50Results
| Group of | Animal number (only) | HC50 | p value |
| Control | 14 | 51.07±2.17 | -- |
| BB-12 group | 14 | 66.31±3.66 | 0.000** |
| BL-99 group | 14 | 67.43±4.04 | 0.000** |
5.2.2 detection of antibody-producing cells
Mixing the mouse spleen cell suspension immunized by Sheep Red Blood Cells (SRBC) with a certain amount of SRBC, and dissolving the SRBC around the spleen cells secreting the antibody in the presence of complement to form macroscopic plaques, wherein the number of the hemolytic plaques can reflect the number of antibody-producing cells.
After the animals were continuously given the samples for 28 days, each mouse was intraperitoneally administeredImmunization was performed with SRBC injection of 0.2 mL. Mice immunized with SRBC for 4 days were sacrificed, and the spleen was removed and prepared into 5X106Individual cells/mL of cell suspension. Heating agarose for dissolving, mixing with equal amount of double Hank's solution, subpackaging into small tubes with 0.5mL per tube, adding 20% (V/V, prepared with normal saline) into the tubes, pressing to obtain 50 μ L SRBC and 200 μ L spleen cell suspension, rapidly mixing, pouring onto six-well plate with agarose thin layer, coagulating with agar, placing into carbon dioxide incubator for continuous incubation for 1h, adding complement (1:10) diluted with SA buffer solution, continuously incubating for 2h, and counting number of hemolytic plaques.
The results of the number of antibody-producing cells are shown in Table 6, in which the sample group and the control group showed significant difference (p < 0.05) between BL-99 and BB-12 groups compared to the control group, and BL-99 group compared to the control group showed significant difference (p > 0.05).
TABLE 6 results of the number of antibody-producing cells
| Group of | Animal number (only) | Number of hemolytic plaques/106Spleen cell | p value |
| Control | 11 | 18.64±1.91 | -- |
| BB-12 |
10 | 23.30±3.13 | 0.003** |
| BL-99 group | 9 | 28.67±2.87 | 0.000** |
5.3NK cell Activity assay
5.3.1 ConA-induced mouse lymphocyte transformation experiments
After 28 days of continuous animal sampling, mice were sacrificed, after sterilization in a beaker of 75% alcohol, spleens were aseptically taken, placed in a small plate containing 3cm × 3cm four layers of gauze (autoclaved), an appropriate amount of sterile Hank's solution was added, splenomeles were crushed with gauze, the spleens were gently crushed with an elbow walk on tiptoe to prepare a single cell suspension, washed 2 times with Hank's solution, centrifuged at 1000rpm for 10min each time, then the cells were suspended in 2mL of complete culture solution, the number of viable cells was counted, and the cell concentration was adjusted to 5 × 106one/mL. The cell suspension was added to the 24-well culture medium in two wells, 1mL per well, and 75. mu.L of LCoA solution (equivalent to 7.5. mu.g/mL) was added to one well, and the other well was used as a control and incubated at 37 ℃ in 5% CO2 for 72 hours. 4 hours before the end of the culture, 0.7mL of the supernatant RPMI1640 medium containing no calf serum was gently aspirated from each well, and 50. mu.L of MTT (5mg/mL) was added to each well, and the culture was continued for 4 hours. After the culture is finished, 1mL of acidic isopropanol is added into each hole, and the mixture is uniformly blown and beaten to ensure that the purple crystals are completely dissolved. Then, the cells were plated in 96-well plates, each well was plated in 2 wells as a parallel sample, and the optical density was measured at a wavelength of 570nm using an enzyme-linked immunosorbent assay. The proliferative capacity of lymphocytes is expressed as the optical density value of ConA plus wells minus the optical density value of ConA minus wells.
The results are shown in Table 7. As can be seen from Table 7, the BB-12 group was significantly higher than the control group (p < 0.05), while BL-99 was not significantly changed from the control group (p > 0.05).
TABLE 7 results of mouse splenic lymphocyte transformation experiments
5.3.2NK cell Activity assay
The animals were continuously administered for 28 days, and the target cell YAC-1 was subcultured 24h before the start of the experiment, washed 2 times with Hank's solution before use, and the cell concentration was adjusted to 1X 10 with 10% calf serum-containing RPMI1640 complete medium5one/mL (target cells). Sudden death of cervical dislocation of mouse, aseptically taking spleen, preparing into suspension of skin cells, washing with Hank's solution for 2 times, centrifuging at 1000rpm for 10min, resuspending with 2mL RPMI1640 containing 10% calf serum, staining with trypan blue viable cells for counting (viable cell number should be above 95%), adjusting cell concentration to 1 × 107number/mL (effector cells) to give an effective target ratio of 100: 1. 100 mu L of each of the target cells and the effector cells are taken and added into a U-shaped 96-well culture plate, 100 mu L of each of the target cells and the culture solution is added into a natural release hole of the target cells, 100 mu L of each of the target cells and 1% NP40 is added into a maximum release hole of the target cells, and three parallel holes are formed in the above. 37 ℃ and 5% CO2Culturing for 4h in an incubator, centrifuging the 96-well culture plate at 1500rpm for 5min, sucking 100 microliter of supernatant per well, placing the supernatant in a flat-bottomed 96-well culture plate, simultaneously adding 100 microliter of LDH matrix solution, reacting for 3min, adding 30 microliter of 1mol/L HCL solution per well to terminate the reaction, measuring an OD value at 490nm of a microplate reader, and calculating the NK activity according to the following formula:
the results are shown in Table 8. As can be seen from Table 8, the NK cell activity of BL-99 was higher than that of the control group and BB-12, and the difference was significant.
TABLE 8 NK cell Activity results
| Group of | Animal number (only) | Cell Activity (%) | P value |
| Control | 14 | 30.70±3.31 | -- |
| BB-12 group | 14 | 33.38±4.17 | 0.078 |
| BL-99 group | 14 | 47.92±5.63 | 0.000** |
5.4 cellular immune response
5.4.1 delayed type hypersensitivity
After the animals were continuously administered for 28 days, 0.2mL of SRBCC (v/v, prepared with physiological saline) was intraperitoneally injected into each mouse at 2% volume, and after 4 days of sensitization, the thickness of the left hind toe was measured, and the same site was measured 3 times to obtain an average value. Then 20% SRBC 20. mu.L was injected subcutaneously at the measurement site, left rear toe thickness was measured at 24h after injection, and the same site was averaged 3 times to express the degree of DTH as the difference in toe thickness before and after challenge (toe swelling degree).
The results are shown in Table 9. As can be seen from Table 9, the toe thickness of each group of mice was at the same level before SRBC challenge, and the toe swelling of the mice occurred 24 hours after SRBC total, and the swelling degree was expressed by the toe thickness difference before and after the challenge. The BB-12 and BL-99 groups were found to be significantly higher than the control group (p < 0.05) by statistical analysis.
TABLE 9 late allergic toe swelling results in mice
5.4.2 mouse peritoneal macrophage phagocytosis assay
After animals are continuously fed with samples for 28 days, injecting 0.2mL of 2% SRBC into the abdominal cavity of each mouse 4 days before the completion of the gavage to activate the macrophages of the mice, killing the mice by cervical dislocation on the same day of the experiment, injecting 3mL of Hank's solution added with calf serum into the abdominal cavity, gently massaging the abdominal cavity for 20 times to fully wash out the macrophages of the abdominal cavity, then cutting a small opening on the abdominal wall, sucking 0.5mL of mixed solution of the abdominal cavity washing solution, and adding the mixed solution into an agar ring of a glass slide. Placing in an incubator and incubating for 15-20min at 37 ℃. After the incubation is finished, the non-adherent cells are quickly washed out by normal saline, fixed in methanol solution for 1min, and stained by Giemsa for 15 min. Washed clean with distilled water, air dried, and counted by a 40 × microscope for phagocytosis rate and phagocytosis index. The phagocytosis rate is the percentage of phagocytes which phagocytize chicken erythrocytes in every 100 phagocytes; the phagocytosis index is the average number of chicken erythrocytes phagocytosed per phagocyte.
The results were calculated as follows:
the results are shown in Table 10. The result of phagocytosis rate and phagocytosis index of the phagocytes shows that the result of the phagocytosis experiment of the BB-12 group is negative if the phagocytosis rate and phagocytosis index of the BB-12 group are not different from those of the control group; the phagocytosis rate and the phagocytosis index of the BL-99 group are higher than those of the control group, and the phagocytosis experiment result of the macrophages of the BL-99 group is positive.
TABLE 10 macrophage phagocytosis Rate and phagocytosis index results
| Group of | Animal number (only) | Phagocytosis ratio (%) | p value | Phagocytic index | p value |
| Control | 14 | 22.55±1.58 | -- | 0.42±0.04 | -- |
| BB-12 group | 14 | 22.28±2.75 | 0.799 | 0.47±0.04 | 0.055 |
| BL-99 group | 14 | 25.48±2.86 | 0.005** | 0.53±0.04 | 0.000** |
The results prove that the isolated strain Bifidobacterium lactis BL-99 can improve the immune organ index, the non-specific immune function and the specific immune function characteristic of an organism, thereby achieving the purpose of improving the activity of the organism in immunity.
6. Intestinal flora regulating effect
In the study, intestinal flora regulating effects of different doses of active bifidobacterium lactis BL-99 and inactivated strains are respectively detected.
Viable bacteria sample: weighing 1g viable bacteria sample according to sample specification, and suspending to 40ml with PBS solution, wherein viable bacteria concentration is 2.5x109CFU/ml。
High dose group: calculated according to the gavage amount of 0.2ml/10g of the mice, the gavage amount of 20g of the mice is 0.4ml, and the gavage dose of 10 high-dose group mice is9CFU/20g。
The medium dose group: respectively adding 5ml of the high-dose suspension into PBS to reach 50ml of constant volume, calculating according to the gavage amount of 0.2ml/10g of mice, the gavage amount of 20g of mice is 0.4ml, and the gavage amount of 10 medium-dose group mice is 108CFU/20g。
Low dose group: adding PBS into 5ml of the medium-dose group suspension respectively to reach a constant volume of 50ml, calculating according to the gavage amount of 0.2ml/10g of the mice, wherein the gavage amount of 20g of the mice is 0.4ml, and the gavage amount of the low-dose group mice is 107CFU/20g。
Dead bacteria samples: weighing 1g viable bacteria sample according to sample specification, and suspending to 40ml with PBS solution, i.e. viable bacteria concentration is 2.5x109CFU/ml. The concentration is 2.5x109And (3) killing the CFU/ml live bacteria sample bacteria liquid for 20min at 100 ℃. The sample preparation method of the high, medium and low dose groups is the same as that of the viable bacteria group.
The BABL/c mice of 6 weeks old are raised in a clean animal room with temperature of 22 ℃, humidity of 10-60%, 12-hour illumination of alternating light and shade, and fed with standard feed and freely drinking water. Adaptive feeding was performed for 5 days, and 182 mice were randomly divided into 13 groups of 14 mice each, and the grouping was shown in Table 11.
TABLE 11 Experimental grouping for regulating intestinal flora
Before beginning the gavage, the feces of each mouse were collected under sterile conditions, labeled, stored at-20 ℃ and tested for intestinal flora. The test was performed by gavage of 0.2ml/10g for each test substance, the control group was performed by PBS for 1-14 days, and the test groups were performed by gavage of corresponding doses of test substances according to Table 11. Mice were weighed once a week and gavage was adjusted according to body weight. Collecting feces of each mouse under sterile condition after 14 days, marking, storing at-20 deg.C, and detecting intestinal flora.
Before and after the experiment, the body weight of each group of mice has no obvious difference. At phylum level, the relative abundance of Firmicutes (Firmicutes) in the intestinal flora of mice increased and the relative abundance of Bacteroidetes (Bacteroidetes) and Proteobacteria (Proteobacteria) decreased after supplementation with different doses of probiotics. Researches show that the ratio of firmicutes to bacteroidetes has strong correlation with human intestinal diseases, and obese patients tend to reduce the ratio of the firmicutes to the bacteroides. Patients with enteritis and intestinal stress syndrome tend to have higher Proteobacteria (Proteobacteria) abundance.
The effect of BL-99 on gut flora at the genus level is shown in table 12.
TABLE 12 Effect of BL-99 on intestinal flora
At the genus level, BL-99 in the probiotic group mouse intestinal flora significantly increased the relative abundance of Lactobacillus (Lactobacillus) in the mouse intestinal tract compared to the control group, and BL-99 low dose group increased Lactobacillus (Lactobacillus) most significantly. The BL-99 dead bacteria high-dose group has obvious inhibition effect on desulfurization vibrio (Desulfovibrio) and enterobacter (enterobacter).
The inhibitory effect of BL-99 on the pathogenic bacteria helicobacter pylori, Escherichia coli-Shigella is shown in Table 13.
TABLE 13 inhibitory Effect of BL-99 on pathogenic bacteria
The pathogenic bacteria are analyzed, and the result also shows that the BL-99 low-dose group has a remarkable inhibiting effect on Helicobacter pylori (Helicobacter), all groups have an inhibiting effect on Escherichia-Shigella (Escherichia-Shigella), and the killing effect is better.
The experiment shows that the balance of intestinal flora can be adjusted by supplementing BL-99 in the low-dose group, the growth of beneficial bacteria is promoted, harmful bacteria and even pathogenic bacteria are inhibited, and the dead bacteria are also effective, so that the BL-99 or BL-99 dead bacteria in the low-dose group can play a potential health role.
Example 2: dairy product prepared by fermenting leaven containing bifidobacterium lactis BL-99
Preparing a bifidobacterium lactis single-bacterium starter: referring to the fermentation process flow shown in fig. 6, bifidobacterium lactis BL-99 (i.e. bifidobacterium lactis with the preservation number of CGMCC No. 15650) is subjected to anaerobic culture in a TPY liquid culture medium. TPY liquid Medium (g/L): 10.0 parts of hydrolyzed casein, 5.0 parts of soytone, 2.0 parts of yeast powder, 5.0 parts of glucose, 0.5 part of L-cysteine, 2.0 parts of dipotassium phosphate, 0.5 part of magnesium chloride, 0.25 part of zinc sulfate, 0.15 part of calcium chloride, 0.0001 part of ferric chloride, and 801.0 parts of Tween, wherein the pH value is 6.5 +/-0.1. The fermentation broth after primary and secondary amplification culture is centrifuged at 2500rpm for 10min at 4 ℃ to collect the thallus. Freeze drying the collected thallus to obtain BL-99 active bacteria powder as single bacteria starter, and preserving at-18 deg.c below.
The yogurt is prepared by fermenting milk by compounding the single-bacterium leavening agent and a commercial probiotic leavening agent (a compound bacterium containing streptococcus thermophilus, lactobacillus bulgaricus, lactobacillus acidophilus and bifidobacterium) according to the following different proportions.
The formula of the yoghourt comprises the following components: 930g of whole pasteurized milk and 70g of white granulated sugar are purchased per 1000g of fermentation substrate. Proper amount of starter strains.
The yogurt fermentation process comprises the following steps: mixing the whole pasteurized milk and the white granulated sugar, homogenizing, sterilizing, cooling to 37 ℃, inoculating a fermenting agent for anaerobic fermentation, demulsifying after the fermentation is finished, stopping fermentation, and preparing the yoghourt. BL-99 single-bacterium fermentation process: fermenting at 37 deg.C for 15 hr. The fermentation process added with the commercial leavening agent comprises the following steps: fermenting at 43 deg.C for 4.5 hr.
And (3) cold-storing each yoghourt sample at 2-8 ℃, detecting the pH value, the acidity, the total viable count and the number of bifidobacteria of the sample in different storage periods, and determining the following results:
and (3) pH value detection:
| storage time | 1d | 7d | | 21d |
| Ming | ||||
| 0 | 4.35 | 4.35 | 4.29 | 4.25 |
| |
4.36 | 4.28 | 4.25 | 4.22 |
| |
4.32 | 4.22 | 4.18 | 4.17 |
| |
4.63 | 4.48 | 4.37 | 4.47 |
| Ming 4 | 4.6 | 4.59 | 4.45 | 4.46 |
Acidity of the solution0And (4) T detection:
| storage time | 1d | 7d | | 21d |
| Ming | ||||
| 0 | 76 | 78.8 | 79.5 | 81.3 |
| |
78.9 | 82.4 | 82.2 | 85.8 |
| |
79.2 | 83.5 | 85.5 | 88.5 |
| |
70.4 | 71.6 | 76.5 | 70.5 |
| Ming 4 | 75.1 | 74.1 | 78.4 | 76.1 |
Detecting the total viable count cfu/g:
| storage time | 1d | 7d | | 21d |
| Ming | ||||
| 0 | 7.9*108 | 1.5*109 | 1.2*109 | 1.2*109 |
| |
1.4*109 | 1.9*109 | 2.6*109 | 1.4*109 |
| |
1.5*109 | 1.8*109 | 2.0*109 | 1.7*109 |
| |
3.7*108 | 5.2*109 | 7.4*108 | 5.0*108 |
| Ming 4 | 1.3*109 | 1.8*109 | 1.7*109 | 1.7*109 |
Detection of bifidobacterium cfu/g:
in addition, evaluation experiments are carried out on the yoghourt samples, so that the differences of the whole flavors of the Ming 0, Ming 1, Ming 2 and Ming 3 yoghourt samples are not large, and the flavors of all the yoghourt samples are pleasant and acceptable.
Sequence listing
<110> Inmunogu Yili industry group GmbH
<120> fermented dairy product containing bifidobacterium lactis and application thereof
<130>GAI18CN5035
<160>11
<170>SIPOSequenceListing 1.0
<210>1
<211>1398
<212>DNA
<213> Bifidobacterium lactis (Bifidobacterium lactis)
<400>1
gctcccccac aagggtcggg ccaccggctt cgggtgctac ccactttcat gacttgacgg 60
gcggtgtgta caaggcccgg gaacgcattc accgcggcgt tgctgatccg cgattactag 120
cgactccgcc ttcacgcagt cgagttgcag actgcgatcc gaactgagac cggttttcag 180
cgatccgccc cacgtcaccg tgtcgcaccg cgttgtaccg gccattgtag catgcgtgaa 240
gccctggacg taaggggcat gatgatctga cgtcatcccc accttcctcc gagttgaccc 300
cggcggtccc acatgagttc ccggcatcac ccgctggcaa catgcggcga gggttgcgct 360
cgttgcggga cttaacccaa catctcacga cacgagctga cgacgaccat gcaccacctg 420
tgaaccggcc ccgaagggaa accgtgtctc cacggcgatc cggcacatgt caagcccagg 480
taaggttctt cgcgttgcat cgaattaatc cgcatgctcc gccgcttgtg cgggcccccg 540
tcaatttctt tgagttttag ccttgcggcc gtactcccca ggcgggatgc ttaacgcgtt 600
ggctccgaca cgggacccgt ggaaagggcc ccacatccag catccaccgt ttacggcgtg 660
gactaccagg gtatctaatc ctgttcgctc cccacgcttt cgctcctcag cgtcagtgac 720
ggcccagaga cctgccttcg ccattggtgt tcttcccgat atctacacat tccaccgtta 780
caccgggaat tccagtctcc cctaccgcac tccagcccgc ccgtacccgg cgcagatcca 840
ccgttaggcg atggactttc acaccggacg cgacgaaccg cctacgagcc ctttacgccc 900
aataaatccg gataacgctc gcaccctacg tattaccgcg gctgctggca cgtagttagc 960
cggtgcttat tcgaacaatc cactcaacac ggccgaaacc gtgccttgcc cttgaacaaa 1020
agcggtttac aacccgaagg cctccatccc gcacgcggcg tcgctgcatc aggcttgcgc 1080
ccattgtgca atattcccca ctgctgcctc ccgtaggagt ctgggccgta tctcagtccc 1140
aatgtggccg gtcaccctct caggccggct acccgtcaac gccttggtgg gccatcaccc 1200
cgccaacaag ctgataggac gcgaccccat cccatgccgc aaaagcattt cccaccccac 1260
catgcgatgg agcggagcat ccggtattac cacccgtttc caggagctat tccggtgcac 1320
agggcaggtt ggtcacgcat tactcacccg ttcgccactc tcaccccgac agcaagctgc 1380
cagggatccc gttcgact 1398
<210>2
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<220>
Claims (10)
1. A fermented milk product contains Bifidobacterium lactis (Bifidobacterium lactis) with preservation number of CGMCC No. 15650.
2. Fermented dairy product according to claim 1, which is a fermented milk, a flavoured fermented milk or a fermented milk beverage, of the live or sterile type.
3. The fermented dairy product according to claim 1, wherein the bifidobacterium lactis having a accession number CGMCC No.15650 is present in the fermented dairy product in an active or inactivated form.
4. The fermented dairy product of claim 1, wherein the bifidobacterium lactis having a preservation number of CGMCC No.15650 is contained in an amount of 1.0 x10 in the fermented dairy product3CFU/mL～1.0×1010CFU/mL; alternatively, the first and second electrodes may be,
the weight of the bifidobacterium lactis with the preservation number of CGMCC No.15650 is 0.001 to 100mg/mL, preferably 0.01 to 100mg/mL, and more preferably 0.01 to 10mg/mL based on the total weight of the fermented dairy product as 100 percent.
5. The fermented milk product according to claim 1, which is prepared by using raw milk or reconstituted milk as a raw material, with or without addition of other raw materials, sterilizing, inoculating a starter strain comprising bifidobacterium lactis with a preservation number of CGMCC No.15650, and fermenting.
6. The fermented dairy product of claim 5, wherein the starter strain is Bifidobacterium lactis having a accession number CGMCC No. 15650; alternatively, the first and second electrodes may be,
the starter strains comprise bifidobacterium lactis with the preservation number of CGMCC No.15650 and also comprise mixed strains of streptococcus thermophilus and lactobacillus bulgaricus, and the ratio of the number of the viable bacteria of the bifidobacterium lactis to the number of the viable bacteria of the lactobacillus bulgaricus is 1: 1-1: 2; preferably, the starter strain further comprises one or more of lactobacillus acidophilus, other bifidobacterium lactis, bifidobacterium longum, bifidobacterium breve, bifidobacterium infantis, bifidobacterium adolescentis, bifidobacterium bifidum, lactobacillus helveticus, lactobacillus casei and lactobacillus rhamnosus.
7. Application of bifidobacterium lactis with the preservation number of CGMCC No.15650 in preparing fermented dairy products with osteoporosis prevention effect.
8. Application of bifidobacterium lactis with the preservation number of CGMCC No.15650 in preparing fermented dairy products with the effect of regulating the balance of gastrointestinal flora.
9. Application of bifidobacterium lactis with the preservation number of CGMCC No.15650 in preparing fermented dairy products with the effect of improving immunity.
10. Use according to claim 7 or 8 or 9, wherein the fermented milk product is a fermented milk product according to any one of claims 1 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811161152.4A CN110959676B (en) | 2018-09-30 | 2018-09-30 | Fermented milk product containing bifidobacterium lactis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811161152.4A CN110959676B (en) | 2018-09-30 | 2018-09-30 | Fermented milk product containing bifidobacterium lactis and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110959676A true CN110959676A (en) | 2020-04-07 |
| CN110959676B CN110959676B (en) | 2022-11-25 |
Family
ID=70029112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811161152.4A Active CN110959676B (en) | 2018-09-30 | 2018-09-30 | Fermented milk product containing bifidobacterium lactis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110959676B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111419882A (en) * | 2020-05-26 | 2020-07-17 | 北京科拓恒通生物技术股份有限公司 | Bifidobacterium lactis for preventing and treating osteoporosis and application thereof |
| CN112106833A (en) * | 2019-06-21 | 2020-12-22 | 内蒙古伊利实业集团股份有限公司 | Fermented dairy product containing bifidobacterium probiotics as well as preparation method and application of fermented dairy product |
| CN113088465A (en) * | 2021-04-02 | 2021-07-09 | 湖北均瑶大健康饮品股份有限公司 | Bifidobacterium lactis strain J605 and application thereof |
| CN113142301A (en) * | 2021-01-18 | 2021-07-23 | 重庆市天友乳业股份有限公司 | Dairy product capable of improving immunity of organism and preparation method thereof |
| CN113197311A (en) * | 2020-07-03 | 2021-08-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | Lactic acid bacteria composition and preparation method thereof |
| CN113350383A (en) * | 2020-11-26 | 2021-09-07 | 内蒙古伊利实业集团股份有限公司 | Bifidobacterium lactis BL-99 capable of resisting oxidation and regulating blood pressure and application thereof |
| CN113355376A (en) * | 2020-11-26 | 2021-09-07 | 内蒙古伊利实业集团股份有限公司 | Method for synthesizing B vitamins by fermenting bifidobacterium lactis BL-99 and application |
| CN113368195A (en) * | 2021-07-02 | 2021-09-10 | 天津方恒生物科技有限公司 | Fat-reducing and weight-reducing beverage mainly for conditioning health and preparation method thereof |
| CN113862181A (en) * | 2021-09-18 | 2021-12-31 | 河北一然生物科技股份有限公司 | Bifidobacterium lactis RK-7782 with intestinal tract regulating function and application thereof |
| CN110959676B (en) * | 2018-09-30 | 2022-11-25 | 内蒙古伊利实业集团股份有限公司 | Fermented milk product containing bifidobacterium lactis and application thereof |
Citations (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0099530A2 (en) * | 1982-07-13 | 1984-02-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Graft copolymer useful as reinforcements for vinyl chloride polymers and process for preparing the same |
| WO1990005847A1 (en) * | 1988-11-18 | 1990-05-31 | Robert Bosch Gmbh | Fuel injection nozzle for internal combustion engines |
| CN1310883A (en) * | 1999-04-28 | 2001-08-29 | 高等技术学院 | Mask configurable smart power circuit-applications and GS-NMOS devices |
| CN1384711A (en) * | 1999-10-28 | 2002-12-11 | 株式会社养乐多本社 | Fermented foods containing biidobacterium |
| CN1469750A (en) * | 2000-10-13 | 2004-01-21 | ��ʽ�������ֶ౾�� | Bone metabolism improving agent |
| WO2006097024A1 (en) * | 2005-03-17 | 2006-09-21 | Origien Medical Technologies | The preparing method and the use of antiseptic medical dressing. |
| EP2134833A2 (en) * | 2007-03-28 | 2009-12-23 | Alimentary Health Limited | Probiotic bifidobacterium strains |
| CN101623321A (en) * | 2008-07-07 | 2010-01-13 | 贵州秀生堂医药生物有限公司 | Thrombolytic active substance extracted from Guizhou fermented blank bean and product thereof |
| US20110020400A1 (en) * | 2007-03-28 | 2011-01-27 | Macsharry John | Probiotic bifidobacterium strains |
| CN102105065A (en) * | 2008-08-29 | 2011-06-22 | 科.汉森有限公司 | Improvement of growth of bifidobacteria in fermented milk products |
| CN103623293A (en) * | 2012-08-24 | 2014-03-12 | 河源信天然营养品有限公司 | Micro-ecological oral preparation |
| JP2016020339A (en) * | 2014-06-16 | 2016-02-04 | 学校法人産業医科大学 | 1,4-dihydroxy-2-naphthoic acid derivative |
| CN106880040A (en) * | 2017-04-11 | 2017-06-23 | 姜红成 | Prepare the fermentation composition and preparation method with the plant enzyme suitable for the conditioning maintenance of rheumatism osteoarthritis patients |
| CN110959792A (en) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | Solid beverage containing bifidobacterium lactis and application thereof |
| CN110964655A (en) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | Bifidobacterium lactis BL-99 capable of regulating gastrointestinal flora and application thereof |
| CN112106833A (en) * | 2019-06-21 | 2020-12-22 | 内蒙古伊利实业集团股份有限公司 | Fermented dairy product containing bifidobacterium probiotics as well as preparation method and application of fermented dairy product |
| WO2021098755A1 (en) * | 2019-11-20 | 2021-05-27 | 内蒙古伊利实业集团股份有限公司 | New application of bifidobacterium lactis bl-99 in inhibiting intestinal inflammation |
| CN112868800A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Infant formula milk powder containing breast milk oligosaccharide for improving immunity and preparation method thereof |
| US20210253995A1 (en) * | 2018-09-30 | 2021-08-19 | Inner Mongolia Yili Industrial Group Co., Ltd | Lactobacillus paracasei et-22 and use thereof |
| CN113355376A (en) * | 2020-11-26 | 2021-09-07 | 内蒙古伊利实业集团股份有限公司 | Method for synthesizing B vitamins by fermenting bifidobacterium lactis BL-99 and application |
| CN114504106A (en) * | 2020-11-16 | 2022-05-17 | 内蒙古伊利实业集团股份有限公司 | New application of bifidobacterium lactis BL-99 in anti-aging and innate immunity improvement |
| WO2022110725A1 (en) * | 2019-11-29 | 2022-06-02 | 内蒙古伊利实业集团股份有限公司 | Use of bifidobacterium lactis bl-99 in improving infection resistance for intestinal bacteria and intestinal immunity |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110959676B (en) * | 2018-09-30 | 2022-11-25 | 内蒙古伊利实业集团股份有限公司 | Fermented milk product containing bifidobacterium lactis and application thereof |
-
2018
- 2018-09-30 CN CN201811161152.4A patent/CN110959676B/en active Active
Patent Citations (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0099530A2 (en) * | 1982-07-13 | 1984-02-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Graft copolymer useful as reinforcements for vinyl chloride polymers and process for preparing the same |
| WO1990005847A1 (en) * | 1988-11-18 | 1990-05-31 | Robert Bosch Gmbh | Fuel injection nozzle for internal combustion engines |
| CN1310883A (en) * | 1999-04-28 | 2001-08-29 | 高等技术学院 | Mask configurable smart power circuit-applications and GS-NMOS devices |
| CN1384711A (en) * | 1999-10-28 | 2002-12-11 | 株式会社养乐多本社 | Fermented foods containing biidobacterium |
| CN1469750A (en) * | 2000-10-13 | 2004-01-21 | ��ʽ�������ֶ౾�� | Bone metabolism improving agent |
| WO2006097024A1 (en) * | 2005-03-17 | 2006-09-21 | Origien Medical Technologies | The preparing method and the use of antiseptic medical dressing. |
| EP2134833A2 (en) * | 2007-03-28 | 2009-12-23 | Alimentary Health Limited | Probiotic bifidobacterium strains |
| US20110020400A1 (en) * | 2007-03-28 | 2011-01-27 | Macsharry John | Probiotic bifidobacterium strains |
| CN101623321A (en) * | 2008-07-07 | 2010-01-13 | 贵州秀生堂医药生物有限公司 | Thrombolytic active substance extracted from Guizhou fermented blank bean and product thereof |
| CN102105065A (en) * | 2008-08-29 | 2011-06-22 | 科.汉森有限公司 | Improvement of growth of bifidobacteria in fermented milk products |
| CN103623293A (en) * | 2012-08-24 | 2014-03-12 | 河源信天然营养品有限公司 | Micro-ecological oral preparation |
| JP2016020339A (en) * | 2014-06-16 | 2016-02-04 | 学校法人産業医科大学 | 1,4-dihydroxy-2-naphthoic acid derivative |
| CN106880040A (en) * | 2017-04-11 | 2017-06-23 | 姜红成 | Prepare the fermentation composition and preparation method with the plant enzyme suitable for the conditioning maintenance of rheumatism osteoarthritis patients |
| CN110959792A (en) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | Solid beverage containing bifidobacterium lactis and application thereof |
| CN110964655A (en) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | Bifidobacterium lactis BL-99 capable of regulating gastrointestinal flora and application thereof |
| US20210253995A1 (en) * | 2018-09-30 | 2021-08-19 | Inner Mongolia Yili Industrial Group Co., Ltd | Lactobacillus paracasei et-22 and use thereof |
| CN112106833A (en) * | 2019-06-21 | 2020-12-22 | 内蒙古伊利实业集团股份有限公司 | Fermented dairy product containing bifidobacterium probiotics as well as preparation method and application of fermented dairy product |
| WO2021098755A1 (en) * | 2019-11-20 | 2021-05-27 | 内蒙古伊利实业集团股份有限公司 | New application of bifidobacterium lactis bl-99 in inhibiting intestinal inflammation |
| CN112868800A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Infant formula milk powder containing breast milk oligosaccharide for improving immunity and preparation method thereof |
| WO2022110725A1 (en) * | 2019-11-29 | 2022-06-02 | 内蒙古伊利实业集团股份有限公司 | Use of bifidobacterium lactis bl-99 in improving infection resistance for intestinal bacteria and intestinal immunity |
| CN114504106A (en) * | 2020-11-16 | 2022-05-17 | 内蒙古伊利实业集团股份有限公司 | New application of bifidobacterium lactis BL-99 in anti-aging and innate immunity improvement |
| CN113355376A (en) * | 2020-11-26 | 2021-09-07 | 内蒙古伊利实业集团股份有限公司 | Method for synthesizing B vitamins by fermenting bifidobacterium lactis BL-99 and application |
Non-Patent Citations (1)
| Title |
|---|
| 沈廷等: "直接染料的好氧生物降解性能研究", 《贵州环保科技》 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110959676B (en) * | 2018-09-30 | 2022-11-25 | 内蒙古伊利实业集团股份有限公司 | Fermented milk product containing bifidobacterium lactis and application thereof |
| CN112106833A (en) * | 2019-06-21 | 2020-12-22 | 内蒙古伊利实业集团股份有限公司 | Fermented dairy product containing bifidobacterium probiotics as well as preparation method and application of fermented dairy product |
| CN112106833B (en) * | 2019-06-21 | 2022-12-02 | 内蒙古伊利实业集团股份有限公司 | Fermented dairy product containing bifidobacterium probiotics as well as preparation method and application of fermented dairy product |
| CN111419882A (en) * | 2020-05-26 | 2020-07-17 | 北京科拓恒通生物技术股份有限公司 | Bifidobacterium lactis for preventing and treating osteoporosis and application thereof |
| CN111419882B (en) * | 2020-05-26 | 2022-07-29 | 北京科拓恒通生物技术股份有限公司 | Bifidobacterium lactis for preventing and treating osteoporosis and application thereof |
| CN113197311A (en) * | 2020-07-03 | 2021-08-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | Lactic acid bacteria composition and preparation method thereof |
| CN113355376A (en) * | 2020-11-26 | 2021-09-07 | 内蒙古伊利实业集团股份有限公司 | Method for synthesizing B vitamins by fermenting bifidobacterium lactis BL-99 and application |
| CN113350383A (en) * | 2020-11-26 | 2021-09-07 | 内蒙古伊利实业集团股份有限公司 | Bifidobacterium lactis BL-99 capable of resisting oxidation and regulating blood pressure and application thereof |
| CN113142301A (en) * | 2021-01-18 | 2021-07-23 | 重庆市天友乳业股份有限公司 | Dairy product capable of improving immunity of organism and preparation method thereof |
| CN113142301B (en) * | 2021-01-18 | 2023-08-08 | 重庆市天友乳业股份有限公司 | Dairy product capable of improving immunity of organism and preparation method thereof |
| CN113088465A (en) * | 2021-04-02 | 2021-07-09 | 湖北均瑶大健康饮品股份有限公司 | Bifidobacterium lactis strain J605 and application thereof |
| CN113368195A (en) * | 2021-07-02 | 2021-09-10 | 天津方恒生物科技有限公司 | Fat-reducing and weight-reducing beverage mainly for conditioning health and preparation method thereof |
| CN113862181A (en) * | 2021-09-18 | 2021-12-31 | 河北一然生物科技股份有限公司 | Bifidobacterium lactis RK-7782 with intestinal tract regulating function and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110959676B (en) | 2022-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110959676B (en) | Fermented milk product containing bifidobacterium lactis and application thereof | |
| CN110964656B (en) | Bifidobacterium lactis BL-99 capable of preventing osteoporosis and application thereof | |
| JP5710250B2 (en) | Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis | |
| TWI572354B (en) | Composition for suppressing inflammation | |
| EP2179028B1 (en) | A novel strain of bifidobacterium and active peptides against rotavirus infections | |
| CN110964657B (en) | Bifidobacterium lactis BL-99 capable of improving immunity and application thereof | |
| US11298382B2 (en) | Bifidobacterium lactis BL-99 and application thereof | |
| RU2704133C2 (en) | Using lactobacillus paracasei for enhancing recovery of variety of intestinal microflora after dysbacteriosis | |
| JP5925274B2 (en) | Endometriosis prevention and / or amelioration agent and food and beverage composition comprising the same | |
| KR102181606B1 (en) | Probiotic strains for the treatment and/or prevention of diarrhea | |
| CN113755409B (en) | Bifidobacterium longum for relieving insulin resistance and application thereof | |
| CN113249280B (en) | Streptococcus thermophilus STN26, bacterium powder and application in uric acid reducing product | |
| CN101808527A (en) | probiotics for inducing satiety and/or satiation | |
| CN110893193A (en) | Novel application of bifidobacterium lactis BL-99 | |
| CN110959792B (en) | Solid beverage containing bifidobacterium lactis and application thereof | |
| RU2577994C1 (en) | Reuterin-producing lactobacillus brevis | |
| US20150284675A1 (en) | Streptococcus thermophilus strains for treating helicobacter pylori infection | |
| RU2584600C2 (en) | L.bulgaricus STRAIN CAPABLE OF INHIBITING ADHESION OF H.pylori STRAINS TO EPITHELIAL CELLS | |
| RU2491336C1 (en) | Bifidobacterial and lactobacillary consortium for preparing bacterial preparations and dietary supplements for correcting gastrointestinal microflora in individuals of fourteen and older, and method for preparing it, dietary supplement for correcting gastrointestinal microflora in individuals of fourteen and older and bacterial preparation for treating dysbiotic gastrointestinal conditions in individuals of fourteen and older | |
| KR20180110848A (en) | A novel Lactobacillus reuteri BM36301 and a Probiotic Benefits of the same | |
| WO2007023912A1 (en) | Bifidobacterium having effect of inhibiting the adhesion of pathogenic microbes to cells, processed product thereof and food and medicinal composition containing the same | |
| CN117305188B (en) | Lactobacillus acidophilus RZKLa0701 capable of promoting bone growth of children and application thereof | |
| RU2176668C1 (en) | Strain of bacterium lactobacillus acidophilus nv ep 317/402 "narine" tnci used for preparing curative-prophylactic preparations for intestine microflora normalization | |
| CN115948296B (en) | Lactobacillus plantarum for improving musculoskeletal health and/or improving exercise capacity, and composition and application thereof | |
| KR100443080B1 (en) | Streptococcus faecium having activity of reducing cholesterol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |